Condition: C-Met Exon 14 Mutation · Sponsor: Haihe Biopharma Co., Ltd.
Indication:Patients with Advanced c-MET-positive Non-Small Cell Lung Cancer Phase Ib (China only): Approximately 90 patients Phase Ⅱ (globally): Approximately 78 evaluable patients; addition of at least 6 patients in Safety Run-in (US only)
This description comes directly from the study's public registry record.
Shun LU, Doctor · +86-21-22200000ext2153 · shun_lu@hotmail.com
Always discuss trial participation with your own doctor first.
| Norton Cancer Institute | Louisville, Kentucky, United States | Not Yet Recruiting |
| The Oncology Institute of Hope & Innovation | Louisville, Kentucky, United States | Recruiting |
| Anhui Province Hospital | Hefei, Anhui, China | Recruiting |
| The Chest Hospital of Anhui Province | Hefei, Anhui, China | Recruiting |
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Beijing Cancer Hospita | Beijing, Beijing Municipality, China | Recruiting |
| Peking Union Medical College Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Union Medical College Hospital Affiliated to Fujian Medical University | Fuzhou, Fujian, China | Recruiting |
| The First Affiliated Hospital of Guangzhou Medical University | Guangzhou, Guangdong, China | Recruiting |
| Cancer Hospital Affiliated to Guangxi Medical University | Nanning, Guangxi, China | Recruiting |
| Hainan Cancer Hospital | Haikou, Hainan, China | Recruiting |
| Cancer Hospital Affiliated to Harbin Medical University | Harbin, Heilongjiang, China | Recruiting |
+ 32 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04270591